Skip to main content
SpringerLink
Log in

Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer

  • Conference paper
Biology of Renal Cell Carcinoma

  • 42 Accesses

Abstract

We have previously reported the results of two multicenter European studies, investigating the efficacy and toxicity of continuous infusion Interleukin-2 (IL-2) alone (1) and IL-2 with LAK cells (2). The therapeutic outcome of these studies was in accordance with the results published in the world literature (3). This means that the response rates were between 15 and 25% and that the overall median survival of 8 months did not appear different from that observed in non-selected historical and IL-2 treated controls (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Von der Maase H, Geertsen P, Thatcher N, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma-a European multicenter phase II study. Eura J Cancer 27: 1583–1589, 1991.

    Google Scholar 

  2. Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer Clin Oncol 25: 21–28, 1989.

    Google Scholar 

  3. Osterwalder B. Clinical studies with interleukin-2: an overview. In: Veronesi U, ed. Lymphohaematopoietic growth factors in cancer therapy II. Berlin Springer-Verlag 1992: 57–86.

    Google Scholar 

  4. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475–480, 1992.

    PubMed  CAS  Google Scholar 

  5. Cameron R, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810–5817, 1988.

    PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874, 1989.

    PubMed  CAS  Google Scholar 

  7. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2a in cancer patients: A phase I study. J Clin Oncol 7: 1726–1732, 1989.

    PubMed  CAS  Google Scholar 

  8. WHO handbook for reporting results of cancer treatment Geneva 1979.

    Google Scholar 

  9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Ass 53: 457–481, 1958.

    Article  Google Scholar 

  10. Kruit WHJ, Bolhuis RLH, Goey SH, et al. Interleukin-2 induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 11: 000–000, 1993.

    CAS  Google Scholar 

  11. Budd GT, Osgood B, Barna B, et al. Phase I clinical trial of interleukin-2 and a-interferon: Toxicity and immunologic effects. Cancer Res 49: 6432–6436, 1989.

    PubMed  CAS  Google Scholar 

  12. Hirsch M, Lipton A, Harvey H, et al. Phase I study of interleukin-2 and interferona2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8: 1657–1663, 1990.

    Google Scholar 

  13. Bukowski RM, Murthy S, Sergi J, et al. Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-a2a: Clinical effects. J Biol Response Mod 9: 538–545, 1990.

    PubMed  CAS  Google Scholar 

  14. Sznol M, Mier JW, Sparano J, et al. A phase I study of high-dose interleukin-2 in combination with interferon-2b. J Biol Response Mod 9: 529–537, 1990.

    PubMed  CAS  Google Scholar 

  15. Rosenberg SA. Adoptive cellular therapy in patients with advanced cancer; An update. Biol Ther Cancer 1: 1–15, 1991.

    Google Scholar 

  16. Atzpodien J, Allhoff E, Korfer A, et al. Treatment strategies in patients with metastatic renal carcinoma. Onkologie 15 (s): 24, 1992.

    Google Scholar 

  17. Ilson DH, Motzer RJ, Kradin RL, et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10: 1124–1130, 1992.

    PubMed  CAS  Google Scholar 

  18. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10: 414–421, 1992.

    CAS  Google Scholar 

  19. Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 10: 804–809, 1992.

    PubMed  CAS  Google Scholar 

  20. Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group trial. Mol Biother 4: 4–9, 1992.

    PubMed  CAS  Google Scholar 

  21. Thomas H, Barton C, Saini A, Dalgleish A, Waxman J. Sequential interleukin2 and alpha interferon for renal cell carcinoma and melanoma. Eur J Cancer 28: 1047–1049, 1992.

    Article  Google Scholar 

  22. Lipton A, Harvey H, Givant E, et al. Interleukin-2 and interferon a-2a outpatient therapy for metastatic renal cell carcinoma. J Immunoth 13: 122–129, 1993.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek), Rotterdam, The Netherlands

    Gerrit Stoter M.D. Ph.D, Hoo Goey M.D., Wim H. J. Kruit M.D. & Brenda Visser R.N.

  2. Department of Clinical and Tumor Immunology, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek), Rotterdam, The Netherlands

    Cor Lamers Ph.D, Jan-Willem Gratama Ph.D & Reinder L. H. Bolhuis Ph. D

  3. Department of Surgery, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek), Rotterdam, The Netherlands

    Alexander M. M. Eggermont M.D. Ph.D

Authors
  1. Gerrit Stoter M.D. Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hoo Goey M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wim H. J. Kruit M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cor Lamers Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan-Willem Gratama Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brenda Visser R.N.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexander M. M. Eggermont M.D. Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Reinder L. H. Bolhuis Ph. D
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag New York Inc.

About this paper

Cite this paper

Stoter, G. et al. (1995). Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer. In: Biology of Renal Cell Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2536-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2536-2_20

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7571-8

  • Online ISBN: 978-1-4612-2536-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation